Search Site

James M. McKiernan, MD

  • John K. Lattimer Professor of Urology
  • Chair, Department of Urology
  • Director, Urologic Oncology

This provider accepts new patients

Appointment Phone Number: (212) 305-0114

James M. McKiernan, MD

James McKiernan, MD, the John K. Lattimer Professor of Urology, is the chair of the Department of Urology of the College of Physicians and Surgeons and urologist-in-chief at NewYork-Presbyterian/Columbia. Dr. McKiernan is only the sixth physician to hold this title since the founding of the department in 1917. The Department of Urology, one of the oldest and most distinguished in the nation, consistently ranks among the top in New York and throughout the United States. NewYork-Presbyterian's urology program ranked No. 5 in the latest U.S. News & World Report ranking of America's best hospitals. In 2015, the department ranked No. 7 in NIH grant funding among academic Urology departments in America.

Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused in urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness reseach in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.

For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.

Board Certifications

  • Urology

Areas of Expertise

  • Urologic Oncology
  • Testicular Cancer
  • Prostate Cancer
  • Kidney & Adrenal Cancer
  • Cancer Care
  • Bladder Cancer
  • Urologic Cancer
  • Genitourinary Surgery
  • Kidney Cancer
  • Bladder Tumor
  • Major Bladder Reconstruction

Languages Spoken

  • Spanish

Education & Training

  • Columbia University College of Physicians and Surgeons
  • MD, 1993 Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center, NY

Locations

  • Herbert Irving Pavilion

    161 Fort Washington Avenue
    Floor: 11
    New York, NY 10032
    Phone:
    (212) 305-0114
    For new and current patient appointments, call:
    (212) 305-0114
    Fax:
    (212) 305-6813
  • ColumbiaDoctors Tarrytown

    155 White Plains Road
    Floor: 1
    Tarrytown, NY 10591
    Phone:
    (212) 305-0114
    For new and current patient appointments, call:
    (212) 305 0114

Contact Info

  • Office Phone: 212-305-5526

NIH Grants

  • A PHASE I TRIAL FOR THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF BCG-REFRACTORY NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER (P&S Industry Clinical Trial)

    Jul 31 2014 - Jul 31 2019

    AN INTEGRATED PHASE II/III, OPEN LABEL, RANDOMIZED, PARALLEL AND CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CARCINOMA IN SITU DISEASE (?NMIBCIS?, MEANING CIS AND CIS WITH (P&S Industry Clinical Trial)

    Mar 31 2014 - Apr 3 2019

    INVESTIGATION OF A NONPARTICLE ALBUMIN-BOUND MTOR INHIBITOR, NABRAPAMYCIN, FOR THE INTRAVESICAL TREATMENT OF BCG RECURRENT OR REFRACTORY NON-MUSCLE INVASIVE TRANSITIONAL CELL BLADDER CANCER (Federal Gov)

    Apr 1 2013 - Dec 31 2016

    EN3348-303 (P&S Industry Clinical Trial)

    May 2 2011 - May 2 2016

    COLUMBIA PCF EXOSOME GRANT APPLICATION (Private)

    Mar 1 2012 - Feb 28 2014

    EXOSOME (Private)

    Feb 11 2011 - Jun 30 2012